This calculator is provided for informational and educational purposes only. It is not intended to replace professional medical advice, diagnosis, or treatment. Always consult with a qualified healthcare professional before making any medical decisions. The results from this calculator should be used as a reference guide only and not as the sole basis for clinical decisions.
Fractional Excretion of Urea (FEUrea) Calculator
Calculate the fractional excretion of urea to differentiate prerenal azotemia from intrinsic renal disease in patients with acute kidney injury. This FEUrea calculator is especially valuable when patients are on diuretics and the fractional excretion of sodium (FENa) is unreliable. Enter serum and urine creatinine and urea values to get instant classification with clinical decision pathway guidance based on the Carvounis 2002 evidence-based thresholds.
FEUrea below 35% indicates the kidneys are conserving urea appropriately in response to reduced perfusion. This result is reliable even in patients receiving diuretics.
| Parameter | FEUrea | FENa |
|---|---|---|
| Prerenal Cutoff | < 35% | < 1% |
| Intrinsic Cutoff | > 50% | > 2% |
| Indeterminate Zone | 35 – 50% | 1 – 2% |
| Reliable with Diuretics | Yes | No |
| Reliable with CKD | Possibly better | Limited |
| Primary Reabsorption Site | Proximal tubule | Loop of Henle / DCT |
| Key Study | Carvounis 2002 | Espinel 1976 |
| Sensitivity (meta-analysis) | 66% | 77-89% |
| Specificity (meta-analysis) | 75% | 79% |
About This Fractional Excretion of Urea (FEUrea) Calculator
This fractional excretion of urea calculator is designed for clinicians, nephrologists, internists, emergency physicians, and critical care providers evaluating patients with acute kidney injury (AKI). It computes the FEUrea from four routine laboratory measurements – serum creatinine, serum urea (BUN), urine creatinine, and urine urea – to help classify AKI as prerenal or intrinsic in etiology.
The calculator applies the standard FEUrea formula with automatic unit conversion between mg/dL, umol/L, mmol/L, BUN, and urea reporting conventions. When you change units, the entered value is automatically converted so the underlying clinical data stays the same and the FEUrea result remains unchanged. It classifies results using the evidence-based thresholds established by the landmark Carvounis study (Kidney International, 2002): FEUrea below 35% for prerenal azotemia, 35-50% for indeterminate cases, and above 50% for intrinsic renal disease such as acute tubular necrosis.
The diagnostic zone bar provides an immediate visual representation of where the patient’s FEUrea falls on the clinical spectrum, while the decision tree displays the appropriate clinical pathway with numbered management steps. The calculation breakdown tab always shows the formula applied in standardized mg/dL units so you can verify the math regardless of which input units you selected. Unlike the fractional excretion of sodium (FENa), FEUrea remains reliable in patients receiving loop or thiazide diuretics.
This calculator is provided for informational and educational purposes only. It is not intended to replace professional medical advice, diagnosis, or treatment. Always consult with a qualified healthcare professional before making any medical decisions. The results from this calculator should be used as a reference guide only and not as the sole basis for clinical decisions.
Fractional Excretion of Urea (FEUrea) – Complete Guide to Renal Failure Differential Diagnosis
Acute kidney injury (AKI) remains one of the most common and consequential clinical encounters in hospital medicine. When a patient presents with rising serum creatinine and declining urine output, clinicians face a critical question: is the kidney failing because it is not receiving enough blood (prerenal azotemia), or because the kidney tissue itself is damaged (intrinsic renal disease, such as acute tubular necrosis)? The distinction matters enormously because the treatment pathways diverge sharply. Prerenal azotemia typically responds to volume repletion and hemodynamic optimization, while intrinsic AKI often requires supportive care, avoidance of nephrotoxins, and sometimes renal replacement therapy.
Traditionally, the fractional excretion of sodium (FENa) has served as the workhorse urinary biomarker for this differentiation. A FENa below 1% suggests prerenal azotemia, while values above 2% point toward intrinsic renal disease. However, FENa has a well-documented weakness: it becomes unreliable in patients receiving diuretics. Diuretics inhibit sodium reabsorption in the tubules, artificially elevating FENa even when the underlying cause is prerenal. This limitation is clinically significant because a large proportion of hospitalized patients with AKI are already on diuretic therapy.
The fractional excretion of urea (FEUrea) was developed as an alternative biomarker to address this specific limitation. Because urea reabsorption occurs primarily in the proximal tubule and is driven largely by passive forces and hormonal regulation (antidiuretic hormone, aldosterone), it is theoretically less affected by loop and thiazide diuretics that act on more distal segments of the nephron. The landmark study by Carvounis and colleagues in 2002 established that a FEUrea cutoff of 35% could effectively differentiate prerenal azotemia from acute tubular necrosis, even in patients receiving diuretic therapy.
Urine Urea = Urea concentration in urine (mg/dL or mmol/L)
Serum Creatinine = Creatinine concentration in blood (mg/dL or umol/L)
Serum Urea = Urea concentration in blood, also known as BUN (mg/dL or mmol/L)
Urine Creatinine = Creatinine concentration in urine (mg/dL or mmol/L)
Note: All values must use consistent units. The formula works with any unit system as long as urea values use the same units and creatinine values use the same units.
Understanding Urea Physiology and Renal Handling
Urea is the primary end product of protein metabolism in mammals. It is synthesized in the liver through the urea cycle, where ammonia (a toxic byproduct of amino acid catabolism) is converted into the relatively nontoxic, water-soluble urea molecule. Urea has a molecular weight of 60 daltons and circulates freely in the plasma. It accounts for approximately 50% of urinary solute excretion and 90% to 95% of total urinary nitrogen excretion under normal conditions.
In the kidney, urea is freely filtered at the glomerulus due to its small size. However, its subsequent handling along the nephron is complex and clinically relevant. In the proximal tubule, approximately 40% to 60% of filtered urea is passively reabsorbed, following the concentration gradient created by water reabsorption. In the thin descending limb of the loop of Henle, urea is secreted into the tubular fluid. The thin ascending limb is relatively impermeable to urea. In the medullary collecting duct, under the influence of antidiuretic hormone (ADH, also called vasopressin), urea transporters (particularly UT-A1 and UT-A3) facilitate urea reabsorption, which is critical for maintaining the medullary concentration gradient necessary for urine concentration.
This physiological framework explains why FEUrea is useful in differentiating prerenal from intrinsic AKI. In prerenal states, reduced renal perfusion triggers the renin-angiotensin-aldosterone system (RAAS) and increases ADH secretion. These neurohormonal responses enhance proximal tubular water and urea reabsorption, leading to decreased urea excretion and a low FEUrea (typically below 35%). In contrast, intrinsic renal disease damages the tubular epithelium, impairing its ability to reabsorb urea. The result is increased urea excretion and a higher FEUrea (typically above 50%).
Urea reabsorption occurs primarily in the proximal tubule and medullary collecting duct, driven by passive concentration gradients and ADH-regulated transporters. Loop diuretics (furosemide) and thiazide diuretics act on the loop of Henle and distal convoluted tubule, respectively, which are downstream from the major sites of urea reabsorption. This anatomical separation explains why FEUrea remains a reliable marker of prerenal physiology even when diuretics have artificially elevated FENa.
Clinical Interpretation of FEUrea Results
The interpretation of FEUrea follows a three-tier classification system based on the degree of urea excretion relative to creatinine clearance. The primary clinical cutoff, established by the landmark Carvounis study, is 35%. Values below this threshold suggest that the kidneys are appropriately conserving urea in response to reduced perfusion, consistent with a prerenal etiology. Values above this threshold suggest tubular dysfunction and point toward intrinsic renal disease.
A FEUrea less than 35% is suggestive of prerenal azotemia. In this scenario, the kidneys are responding appropriately to perceived hypovolemia or reduced effective circulating volume by maximizing urea reabsorption. Common clinical scenarios include dehydration, hemorrhage, congestive heart failure with reduced cardiac output, sepsis-related systemic vasodilation, and hepatorenal syndrome. The Carvounis study found that 89% of patients with prerenal azotemia (including those on diuretics) had a FEUrea below 35%.
A FEUrea between 35% and 50% falls into an indeterminate zone. Values in this range may represent early or evolving intrinsic renal injury, a mixed prerenal and intrinsic picture, or a transitional state. Clinical correlation with the patient’s history, volume status, medication exposure, and trajectory of kidney function is essential when FEUrea falls in this range.
A FEUrea greater than 50% is strongly suggestive of intrinsic renal disease, most commonly acute tubular necrosis (ATN). In the Carvounis study, the mean FEUrea in the ATN group was 58.6% (+/- 3.6%). Intrinsic causes of elevated FEUrea include ischemic ATN, nephrotoxic ATN (from aminoglycosides, contrast agents, or cisplatin), acute interstitial nephritis, and glomerulonephritis.
FEUrea less than 35%: Suggests prerenal azotemia (kidneys are conserving urea appropriately). FEUrea 35% to 50%: Indeterminate zone requiring clinical correlation. FEUrea greater than 50%: Suggests intrinsic renal disease (tubular damage impairing urea reabsorption). In well-hydrated individuals with normal kidney function, FEUrea typically ranges from 50% to 65%.
The Carvounis Study and Evidence Base
The foundational evidence for FEUrea comes from the prospective study published by Carvounis, Nisar, and Guro-Razuman in Kidney International in December 2002. This study evaluated 102 episodes of acute renal failure at Nassau University Medical Center and the State University of New York at Stony Brook. Patients were divided into three groups: those with prerenal azotemia not receiving diuretics (n=50), those with prerenal azotemia receiving diuretics (n=27), and those with acute tubular necrosis (n=25).
The study’s key findings demonstrated that FENa was low (less than 1%) in 92% of patients with untreated prerenal azotemia, but in only 48% of those with prerenal azotemia who were on diuretics. This confirmed the well-known limitation of FENa in the setting of diuretic therapy. In contrast, FEUrea was essentially identical in the two prerenal groups (27.9% +/- 2.4% in the untreated group versus 24.5% +/- 2.3% in the diuretic-treated group), and markedly different from the ATN group (58.6% +/- 3.6%, p less than 0.0001). Furthermore, 89% of the diuretic-treated prerenal patients had a FEUrea below 35%, compared to only 48% who had a FENa below 1%.
Subsequent studies have both supported and challenged these findings. A multicenter cohort study by Darmon and colleagues in Critical Care (2011) evaluated 203 critically ill patients and found more modest diagnostic performance, with sensitivity of 63% and specificity of 54% at the 35% cutoff. A systematic review and meta-analysis published in 2024 by Alhroob and colleagues, encompassing 11 studies and 1,108 patients, reported pooled sensitivity of 66% and specificity of 75% for FEUrea greater than 35% in distinguishing intrinsic from prerenal AKI. These results suggest that while FEUrea is a useful clinical tool, it should be interpreted in conjunction with other clinical parameters and biomarkers rather than used in isolation.
FEUrea Versus FENa: Complementary Biomarkers
FEUrea and FENa are best understood as complementary rather than competing biomarkers. Each has specific clinical scenarios where it excels and situations where its reliability is diminished. Understanding these nuances helps clinicians choose the most appropriate test for each patient.
FENa (fractional excretion of sodium) remains the first-line urinary biomarker in most clinical settings. Its cutoff values are well established: FENa less than 1% suggests prerenal azotemia, while FENa greater than 2% suggests intrinsic renal disease. FENa performs well in patients who are not receiving diuretics, those without chronic kidney disease, and those without conditions that cause low urinary sodium independent of prerenal physiology (such as contrast nephropathy, myoglobinuria, and early obstructive uropathy).
FEUrea becomes particularly valuable in specific clinical contexts. It is the preferred biomarker when patients are receiving loop diuretics (furosemide, bumetanide, torsemide) or thiazide diuretics, as these medications artificially elevate FENa but have minimal effect on urea reabsorption. FEUrea is also useful in patients with chronic kidney disease, where baseline FENa may already be elevated. Additionally, FEUrea can serve as a confirmatory test when FENa results are discordant with the clinical picture.
The ideal clinical approach is to obtain both FENa and FEUrea simultaneously when evaluating a patient with AKI. Concordant results (both suggesting prerenal or both suggesting intrinsic disease) provide stronger diagnostic confidence. Discordant results should prompt careful clinical reassessment and consideration of confounding factors.
FEUrea is preferred over FENa when the patient is receiving diuretics (loop or thiazide), when the patient has underlying chronic kidney disease with baseline sodium wasting, when FENa results are discordant with clinical assessment, or when the clinical scenario involves conditions known to cause false-low FENa (contrast nephropathy, rhabdomyolysis, early urinary obstruction). Using both biomarkers together provides the most robust diagnostic information.
Clinical Scenarios and Practical Application
Understanding how FEUrea performs in real-world clinical scenarios helps clinicians apply the calculator effectively. Several common clinical situations merit specific discussion.
In congestive heart failure, patients often present with AKI due to reduced cardiac output and decreased renal perfusion. Many of these patients are already receiving loop diuretics. In this setting, FENa is often misleadingly elevated, while FEUrea accurately identifies the prerenal component of kidney injury. A low FEUrea in a heart failure patient with AKI supports aggressive optimization of cardiac output and careful diuretic management rather than empiric fluid loading.
In cirrhosis and hepatorenal syndrome, the interpretation of urinary biomarkers requires particular nuance. The study by Patidar and colleagues in Hepatology (2018) examined FEUrea in cirrhotic patients with AKI and found that it could help differentiate between prerenal azotemia, hepatorenal syndrome (HRS), and acute tubular necrosis. Median FEUrea values were statistically different across all three etiologies (prerenal 30.1%, HRS 20.2%, ATN 43.6%), although there was overlap between groups.
In sepsis-associated AKI, the pathophysiology is complex and often involves elements of both prerenal and intrinsic injury. The Darmon multicenter study specifically evaluated FEUrea in critically ill patients, many of whom had sepsis, and found more limited diagnostic performance compared to the original Carvounis study. This finding suggests that in the intensive care setting, AKI etiology often exists on a continuum rather than as discrete categories, and urinary biomarkers should be interpreted cautiously.
In contrast-induced nephropathy, the early phase of injury may paradoxically show a low FENa due to renal vasoconstriction and avid sodium reabsorption, despite intrinsic tubular damage. FEUrea can help clarify the picture in these cases, as true intrinsic injury will elevate FEUrea even when FENa remains misleadingly low.
Laboratory Considerations and Unit Conversions
Accurate calculation of FEUrea requires attention to laboratory units and measurement conventions, which vary across different regions and healthcare systems worldwide. The most common sources of error in FEUrea calculation stem from unit mismatches between serum and urine measurements or confusion between BUN and urea reporting.
In many North American laboratories, urea is reported as blood urea nitrogen (BUN) in mg/dL, which measures only the nitrogen content of the urea molecule. In many European, Australian, and Asian laboratories, urea is reported directly in mmol/L. The conversion between these units requires understanding the molecular relationships. BUN in mg/dL can be converted to urea in mmol/L by multiplying by 0.357 (or dividing by 2.8). Conversely, urea in mmol/L can be converted to BUN in mg/dL by multiplying by 2.8.
For the FEUrea calculation, the critical requirement is consistency: both the serum and urine urea measurements must be in the same units, and both the serum and urine creatinine measurements must be in the same units. The formula produces a ratio, so as long as the units cancel appropriately, the result will be correct regardless of whether mg/dL or mmol/L is used. Similarly, creatinine may be reported in mg/dL (common in North America) or umol/L (common elsewhere). The conversion factor is 88.4 (creatinine in umol/L = creatinine in mg/dL x 88.4).
Some laboratories report urine urea as urine urea nitrogen (UUN) rather than urine urea. If both serum and urine values are reported as nitrogen equivalents (BUN and UUN), the formula works directly without conversion. If one is reported as nitrogen and the other as total urea, the 2.14 conversion factor must be applied to make them consistent.
The FEUrea formula produces a dimensionless ratio (expressed as a percentage), so any consistent unit system will yield the correct result. The most common error is mixing BUN (nitrogen only) with urea (whole molecule) or mixing mg/dL with mmol/L between serum and urine specimens. Always verify what your laboratory is reporting before entering values into the calculator. When in doubt, check whether the lab report header says “Urea” or “BUN” and whether units are mg/dL, mmol/L, or umol/L.
Limitations and Pitfalls of FEUrea
While FEUrea is a valuable clinical tool, it has several important limitations that clinicians should understand. No single urinary biomarker is sufficient to definitively diagnose the cause of AKI, and FEUrea should always be interpreted within the broader clinical context.
First, FEUrea may be falsely low (suggesting prerenal azotemia) in certain intrinsic renal conditions. Early acute tubular necrosis, before full tubular injury has developed, may present with a low FEUrea. Conditions associated with decreased urea production (severe liver disease, low protein intake, malnutrition) can also lower FEUrea independent of renal hemodynamics. Gastrointestinal bleeding increases urea production and reabsorption, which can lower FEUrea and mimic a prerenal pattern even in the setting of intrinsic renal disease.
Second, FEUrea may be falsely elevated (suggesting intrinsic disease) in certain prerenal conditions. High protein intake or hypercatabolic states (burns, trauma, sepsis, corticosteroid use) can increase urea production and excretion, elevating FEUrea despite preserved tubular function. Osmotic diuretics (mannitol) can also increase urea excretion and confound interpretation.
Third, the diagnostic performance of FEUrea varies across clinical populations. As noted above, the original Carvounis study demonstrated excellent performance, but subsequent studies in critically ill patients showed more modest accuracy. The 2024 meta-analysis by Alhroob and colleagues found pooled sensitivity of only 66% and specificity of 75%, suggesting that FEUrea misclassifies a meaningful proportion of patients.
Fourth, FEUrea has not been extensively validated in certain special populations, including pediatric patients, pregnant women, patients with advanced chronic kidney disease (eGFR less than 15 mL/min), and patients on renal replacement therapy. Clinicians should exercise particular caution when interpreting FEUrea in these groups.
Global Application and Population Considerations
The FEUrea calculation was originally developed and validated primarily in North American populations. However, the underlying renal physiology that drives the biomarker is universal across ethnic groups, and the formula has been applied in clinical settings worldwide. Several factors relevant to global application merit discussion.
Laboratory reporting conventions vary significantly across regions. As discussed in the laboratory considerations section, the distinction between BUN and urea reporting, and between mg/dL and mmol/L units, is the most common source of calculation error. Clinicians and laboratory professionals worldwide should be aware of their local reporting conventions and ensure appropriate unit conversion when using the FEUrea calculator.
Dietary protein intake, which varies across populations and cultural dietary patterns, can influence baseline urea levels and potentially affect FEUrea interpretation. Populations with very high protein intake may have higher baseline urea production, while those with predominantly plant-based diets may have lower baseline levels. However, since FEUrea is a ratio, these effects are generally modest and do not significantly alter the diagnostic utility of the standard cutoff values.
The availability and timing of laboratory measurements also varies globally. In resource-limited settings, simultaneous serum and urine measurements may not always be feasible, and specimen collection and processing times may be longer. These practical considerations can affect the reliability of calculated values, as serum and urine samples should ideally be collected at approximately the same time for the ratio to be meaningful.
Validation Across Diverse Clinical Settings
Since the original Carvounis publication, FEUrea has been evaluated in a variety of clinical settings and patient populations. These validation studies provide important context for clinical application.
In the intensive care setting, Darmon and colleagues (Critical Care, 2011) conducted a multicenter cohort study of 203 critically ill patients across eight French ICUs. They found that FEUrea had an area under the receiver operating characteristic (ROC) curve of 0.59 for distinguishing transient from persistent AKI, with sensitivity of 63% and specificity of 54% at the 35% cutoff. The performance was not significantly different in the subgroup receiving diuretics. These findings suggest that in critically ill patients, particularly those with sepsis, the distinction between prerenal and intrinsic AKI may be less clear-cut than in non-ICU settings.
In cirrhotic patients, Patidar and colleagues (Hepatology, 2018) showed that FEUrea could help differentiate between prerenal azotemia, hepatorenal syndrome, and acute tubular necrosis, with an optimal cutoff of approximately 32% for distinguishing functional (prerenal and HRS) from structural (ATN) AKI. This study highlighted the particular value of FEUrea in the hepatology setting, where traditional biomarkers often perform poorly.
In pediatric populations, limited data suggest that FEUrea may be useful, but the standard adult cutoff values have not been rigorously validated in children. Pediatric nephrologists should interpret FEUrea with caution and in conjunction with other clinical parameters when evaluating AKI in children.
Kaplan and Kohn (1992) first described the utility of FEUrea in a small prospective study of patients on diuretics, establishing the concept that urea excretion is less affected by diuretic therapy than sodium excretion. Their work laid the conceptual groundwork for the larger Carvounis study that followed a decade later.
Regional Variations and Alternative Calculators
FEUrea is part of a broader toolkit of urinary biomarkers and indices used to evaluate AKI etiology. Different clinical settings and regional practice patterns may favor different combinations of these tools.
The fractional excretion of sodium (FENa) remains the most widely used urinary index globally. Its well-established cutoff values (less than 1% for prerenal, greater than 2% for intrinsic) make it a natural first-line test in patients not receiving diuretics. FENa and FEUrea are most powerful when used together, as concordant results increase diagnostic confidence.
The urine sodium concentration (UNa) is another commonly used marker. Values below 20 mEq/L suggest prerenal azotemia, while values above 40 mEq/L suggest intrinsic disease. Like FENa, UNa is affected by diuretic therapy. The urine osmolality is also used; values above 500 mOsm/kg suggest prerenal azotemia (preserved concentrating ability), while values below 350 mOsm/kg suggest intrinsic disease.
The BUN-to-creatinine ratio provides additional information about the prerenal versus intrinsic distinction. A ratio greater than 20:1 suggests prerenal azotemia (due to enhanced urea reabsorption), while a ratio less than 20:1 is more consistent with intrinsic disease. However, this ratio is influenced by many factors including diet, gastrointestinal bleeding, catabolic states, and corticosteroid use.
Novel biomarkers such as neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and tissue inhibitor of metalloproteinases-2 with insulin-like growth factor-binding protein 7 (TIMP-2 x IGFBP7, marketed as NephroCheck) are increasingly used to detect tubular injury and predict AKI progression. These biomarkers detect structural kidney damage earlier than traditional markers and may complement FEUrea in comprehensive AKI evaluation.
Step-by-Step Calculation Example
To illustrate the practical application of FEUrea, consider a 68-year-old patient admitted with congestive heart failure exacerbation, currently receiving intravenous furosemide 40 mg twice daily, with rising creatinine from baseline 1.0 mg/dL to 2.4 mg/dL over 48 hours.
The following laboratory values are obtained from simultaneous serum and spot urine samples: Serum creatinine = 2.4 mg/dL. Serum urea (BUN) = 58 mg/dL. Urine creatinine = 84 mg/dL. Urine urea nitrogen = 420 mg/dL.
Since both serum and urine urea are reported as nitrogen values (BUN and UUN), the formula can be applied directly without conversion: FEUrea = (420 x 2.4) / (58 x 84) x 100 = 1008 / 4872 x 100 = 20.7%.
The FEUrea of 20.7% is well below the 35% threshold, strongly suggesting prerenal azotemia despite the patient being on diuretics. This is consistent with the clinical picture of cardiorenal syndrome, where reduced cardiac output leads to decreased renal perfusion. Note that the FENa in this patient might be misleadingly elevated due to furosemide therapy, making FEUrea the more reliable biomarker in this case.
Patient: 68-year-old on IV furosemide with rising creatinine
Serum Cr: 2.4 mg/dL | BUN: 58 mg/dL | Urine Cr: 84 mg/dL | UUN: 420 mg/dL
FEUrea = (420 x 2.4) / (58 x 84) x 100 = 1008 / 4872 x 100 = 20.7%
Interpretation: FEUrea less than 35% – Prerenal azotemia likely. The kidneys are appropriately conserving urea despite diuretic therapy, consistent with cardiorenal physiology.
When to Order FEUrea: Clinical Decision-Making
FEUrea is most useful in specific clinical contexts where the distinction between prerenal and intrinsic AKI has therapeutic implications. Understanding when to order this test helps clinicians use laboratory resources efficiently and obtain actionable information.
The primary indication for FEUrea is evaluation of AKI in patients receiving diuretics. When a patient on loop or thiazide diuretics develops AKI, FENa becomes unreliable, and FEUrea provides a more accurate assessment of the prerenal versus intrinsic distinction. This scenario is extremely common in hospitalized patients, particularly those with heart failure, cirrhosis, or nephrotic syndrome.
FEUrea is also valuable when FENa results are discordant with the clinical picture. If a patient appears clinically volume-depleted but has a FENa greater than 1%, FEUrea can help determine whether the elevated FENa is a true reflection of intrinsic disease or an artifact of medication effects, chronic kidney disease, or other confounders.
In the intensive care setting, FEUrea can complement other urinary indices and novel biomarkers in the evaluation of AKI. While its standalone diagnostic performance may be more modest in critically ill patients (as demonstrated by the Darmon study), it adds incremental value to the overall assessment when used alongside FENa, urine microscopy, and clinical context.
FEUrea is less useful in certain situations. It should not be ordered in patients with known urinary tract obstruction (which has a different diagnostic pathway), those with established end-stage kidney disease on dialysis, or as a screening test in patients without AKI. It is also of limited value in the immediate post-surgical period when hemodynamic instability and fluid shifts make all urinary biomarkers difficult to interpret.
Specimen Collection and Timing
Proper specimen collection is essential for accurate FEUrea calculation. The test requires four simultaneous measurements: serum urea (or BUN), serum creatinine, urine urea, and urine creatinine. The serum and urine specimens should be collected at approximately the same time, ideally within a one-hour window, to ensure the calculated ratio reflects the kidney’s handling of urea at a specific point in time.
A spot urine sample is sufficient for FEUrea calculation; a 24-hour urine collection is not necessary. The spot sample should be collected before any fluid resuscitation or changes in diuretic therapy, as these interventions can rapidly alter urine composition. If the patient has an indwelling urinary catheter, the sample should be obtained from the sampling port, not from the collection bag (which represents a mixture of urine produced over time).
The serum sample is a standard venous blood draw. Both serum creatinine and BUN (or urea) are routine components of a basic metabolic panel or comprehensive metabolic panel in most laboratories, so the serum measurements are often already available. The urine measurements may need to be specifically ordered, as urine urea and urine creatinine are not part of routine urinalysis.
Integrating FEUrea Into Clinical Practice
The optimal approach to AKI evaluation integrates FEUrea with other clinical and laboratory data rather than relying on any single biomarker. A systematic approach to AKI evaluation should include assessment of the patient’s volume status through physical examination and hemodynamic monitoring, review of the medication list for nephrotoxins and diuretics, urinalysis with microscopy to look for muddy brown casts (suggesting ATN), red blood cell casts (suggesting glomerulonephritis), or white blood cell casts (suggesting interstitial nephritis), calculation of FENa and FEUrea from simultaneously collected specimens, review of the BUN-to-creatinine ratio, assessment of urine output trends, and consideration of renal ultrasound to exclude obstruction.
When FEUrea and FENa are concordant (both suggesting the same etiology), the diagnostic confidence is high. When they are discordant, the clinician should consider which test is more likely to be confounded in the specific clinical context. For example, if FENa suggests intrinsic disease but FEUrea suggests prerenal azotemia in a patient on furosemide, the FEUrea is likely more reliable and the elevated FENa is likely a diuretic artifact.
Impact on Patient Management
The accurate determination of AKI etiology through tools like FEUrea has direct implications for patient management. In prerenal AKI, the primary treatment is restoration of adequate renal perfusion through volume repletion (in hypovolemic states), optimization of cardiac output (in cardiorenal syndrome), or treatment of the underlying cause of reduced effective circulating volume. Early recognition of prerenal physiology can prevent progression to intrinsic renal injury if perfusion is restored promptly.
In intrinsic AKI (particularly ATN), management focuses on supportive care: maintaining euvolemia, avoiding additional nephrotoxins, adjusting medication doses for reduced renal function, monitoring for complications of uremia (hyperkalemia, metabolic acidosis, fluid overload), and considering renal replacement therapy if conservative measures fail. Early identification of intrinsic AKI also helps set appropriate expectations for recovery, as ATN typically requires days to weeks for renal function to improve, in contrast to prerenal azotemia which often improves within 24 to 48 hours of adequate resuscitation.
Future Directions in AKI Biomarker Research
The field of AKI biomarker research is rapidly evolving, with novel markers and multi-marker panels showing promise for earlier detection and more accurate classification of kidney injury. While FEUrea remains a useful and widely available tool, it is likely to be increasingly supplemented or potentially superseded by newer biomarkers in the coming years.
Neutrophil gelatinase-associated lipocalin (NGAL), both in serum and urine forms, can detect tubular injury hours before creatinine rises. Kidney injury molecule-1 (KIM-1) is a transmembrane protein shed from injured proximal tubular cells and is highly specific for proximal tubular damage. The combination of tissue inhibitor of metalloproteinases-2 (TIMP-2) and insulin-like growth factor binding protein 7 (IGFBP7), marketed as the NephroCheck test, has been approved for AKI risk assessment and can predict moderate-to-severe AKI within 12 hours.
Artificial intelligence and machine learning approaches are being developed to integrate multiple biomarkers, vital signs, and clinical data into predictive models for AKI classification and outcomes. These models may eventually provide more nuanced risk stratification than any single biomarker can achieve.
Despite these advances, FEUrea retains practical advantages: it is inexpensive, widely available, and requires only routine laboratory measurements. For the foreseeable future, it will remain a valuable component of the AKI evaluation toolkit, particularly in settings where novel biomarkers are not accessible.
Frequently Asked Questions
Conclusion
The fractional excretion of urea (FEUrea) is a valuable clinical tool for differentiating prerenal azotemia from intrinsic renal disease in patients with acute kidney injury. Its primary advantage over the traditional fractional excretion of sodium (FENa) lies in its reliability in patients receiving diuretic therapy, a common clinical scenario in hospitalized patients. The standard cutoff of 35%, established by the landmark Carvounis study in 2002, provides a clinically useful threshold: values below 35% suggest prerenal etiology, while values above 50% point toward intrinsic renal disease such as acute tubular necrosis.
However, like all biomarkers, FEUrea has limitations. Its diagnostic performance is more modest in critically ill patients, it can be confounded by factors affecting urea production and reabsorption, and it cannot definitively diagnose AKI etiology in isolation. The optimal clinical approach integrates FEUrea with FENa, urine microscopy, clinical assessment, and other relevant data to arrive at the most accurate diagnosis and guide appropriate therapy. As newer biomarkers become more widely available, FEUrea will continue to serve as an accessible and informative component of the comprehensive AKI evaluation.